TABLE 2

Observed Toxicities and Further Proceedings

Patient no.	²²⁵Ac activity, first cycle	PLT	WBC	Hb	Xerostomia	Other	Follow-up and further proceedings
1	3.3	G4 → G4	G2	TD → TD	0	0	BSC; PFS 6 wk; OS 16 wk
2	4.5	G4 → G4	0	TD → TD	0	0	OS 7 wk
3	5	0	0	0	0	0	Second cycle, 50 kBq/kg (2-mo interval)
							Third cycle, 50 kBq/kg (2-mo interval)
							Radiologic progression of disease; OS > 8 mo
4	6	0	0	G1 → G1	0	0	OS 8 wk
5	9.0	G1	G2 → G3	G2 → G3	0	0	Second cycle, 100 kBq/kg (4-mo interval)
							Third cycle, 100 kBq/kg (2-mo interval)
							Hematologic toxicity with overlap to DOTATOC followed by cabazitaxel; OS > 24 mo
6	9.0	NA	NA	NA	NA	NA	Combination with docetaxel 75 mg/m² → G5 neutropenia, OS 1 mo
7	10.9	0	0	0	G1	0	Second cycle, 100 kBq/kg (4-mo interval)
							Third cycle, 100 kBq/kg (2-mo interval)
							OS 10 mo
8	16.0	0	0	0	G1	0	Second cycle, 100 kBq/kg (2-mo interval)
							PFS 9 mo
							Third cycle, 100 kBq/kg (start of second series)
							Fourth cycle, 100 kBq/kg (2-mo interval)
							OS 17 mo
9	13.4	0	0	G2 → G1	G1	0	Second cycle, 150 kBq/kg (2-mo interval)
							Third cycle, 125 kBq/kg (4-mo interval)
							OS 20 mo (death not tumor-related)
10	13.4	NA	NA	NA	G1	0	Second cycle, 100 kBq/kg (2-mo interval)
							Third cycle, 100 kBq/kg (2-mo interval)
							Fourth cycle, 100 kBq/kg (2-mo interval)
							Combination with cabazitaxel 10 mg/m² → G3 thrombocytopenia, G3 neutropenia
							OS 12 mo
11	14.3	0	0	0	G2	0	Second cycle, 100 kBq/kg (4-mo interval)
							Switched to TACE; OS 12 mo
12	14.6	0	0	0	G1	0	Switched to TACE; OS 4 mo
13	16.5	G1 → G2	G3	G1 → G2	G1	0	Second cycle, 50 kBq/kg (2-mo interval)
							Third cycle, 50 kBq/kg (2-mo interval)
							OS 7 mo
14	19.1	0	0	0	G2	Nausea G1, fatigue G2, xerophtalmia G2	Discontinued (xerostomia/xerophtalmia)
							OS > 12 mo (lost to follow-up)

PLT = platelets; WBC = white blood cells (total); Hb = hemoglobin; BSC = best supportive care; PFS = progression free survival; OS = overall survival, TD = transfusion dependent.